Savara (SVRA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, with virtual participation available to shareholders.
Shareholders are invited to vote on key proposals, including director elections, amendments to the certificate of incorporation, incentive plan changes, auditor ratification, and executive compensation.
Voting matters and shareholder proposals
Election of six directors to serve until the next annual meeting, with all nominees recommended by the board.
Proposal to amend the certificate of incorporation to increase authorized common stock from 300,000,000 to 600,000,000.
Proposal to amend the 2024 Omnibus Incentive Plan, increasing shares authorized for issuance by 18,900,000.
Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) included.
Board of directors and corporate governance
Six director nominees listed: Matthew Pauls, Nevan Elam, Richard J. Hawkins, Joseph S. McCracken, David A. Ramsay, and An van Es-Johansson.
All nominees are recommended for election by the board.
Latest events from Savara
- Shareholders to vote on board elections, share increase, incentive plan, and executive pay.SVRA
Proxy filing24 Apr 2026 - MOLBREEVI nears FDA priority review, targeting August approval and rapid rare disease market entry.SVRA
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Apr 2026 - Key votes on board, capital, incentives, and auditor as company prepares for product launch.SVRA
Proxy filing10 Apr 2026 - MOLBREEVI shows strong efficacy and safety for autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation7 Apr 2026 - MOLBREEVI demonstrated strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation30 Mar 2026 - Regulatory progress and robust cash position set the stage for a potential 2026 launch.SVRA
Q4 202513 Mar 2026 - MOLBREEVI demonstrated strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation13 Mar 2026 - MOLBREEVI nears FDA approval for autoimmune PAP, with launch prep and strong clinical data.SVRA
The Citizens Life Sciences Conference 202611 Mar 2026 - MOLBREEVI demonstrated significant efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation11 Mar 2026